Are you Dr. Blank?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 77 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1726 Shawano Ave
Green Bay, WI 54303Phone+1 920-884-3135Fax+1 920-884-3144
Summary
- Dr. Jules Blank, MD is an oncologist in Green Bay, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Michigan, and Illinois. He is affiliated with HSHS St. Mary's Hospital Medical Center, HSHS St. Vincent Hospital, and HSHS St. Clare Memorial Hospital.
Education & Training
University of ConnecticutFellowship, Hematology and Medical Oncology, 1981 - 1984
Southern Illinois UniversityResidency, Internal Medicine, 1978 - 1981
Loyola University Chicago Stritch School of MedicineClass of 1978
Certifications & Licensure
MI State Medical License 1994 - 2020
WI State Medical License 1985 - 2019
IL State Medical License 1979 - 1982
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Trial of LBH589 in Metastatic Thyroid Cancer Start of enrollment: 2010 Jan 01
- Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2009 Jul 01
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Publications & Presentations
PubMed
- 34 citationsA phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S. Fenske, Namrata Shah, Kyung Mann Kim, Sandeep Saha, Chong Zhang
Cancer. 2015-10-01 - 43 citationsRandomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate CancerSteven Attia, Jens C. Eickhoff, George Wilding, Douglas G. McNeel, Jules H. Blank
Clinical Cancer Research. 2008-04-15 - 30 citationsVorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyTien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Jill M. Kolesar
Investigational New Drugs. 2014-02-01
Professional Memberships
- Member
